Tag Archives: SNMX

Head to Head Analysis: Senomyx (SNMX) vs. ICON (ICLR)

Senomyx (NASDAQ: SNMX) and ICON (NASDAQ:ICLR) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.


Get Senomyx alerts:

This table compares Senomyx and ICON’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senomyx -5.66% -10.75% -7.06%
ICON 14.80% 27.09% 14.86%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Senomyx and ICON, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senomyx 0 0 0 0 N/A
ICON 0 2 7 1 2.90

ICON has a consensus target price of $125.40, suggesting a potential downside of 0.61%. Given ICON’s higher possible upside, analysts clearly believe ICON is more favorable than Senomyx.

Institutional and Insider Ownership

29.3% of Senomyx shares are held by institutional investors. Comparatively, 91.0% of ICON shares are held by institutional investors. 13.0% of Senomyx shares are held by company insiders. Comparatively, 44.0% of ICON shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Senomyx has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, ICON has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Earnings & Valuation

This table compares Senomyx and ICON’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senomyx $29.32 million 2.24 -$1.26 million ($0.03) -45.33
ICON $1.76 billion 3.88 $281.48 million $5.39 23.41

ICON has higher revenue and earnings than Senomyx. Senomyx is trading at a lower price-to-earnings ratio than ICON, indicating that it is currently the more affordable of the two stocks.


ICON beats Senomyx on 13 of the 14 factors compared between the two stocks.

About Senomyx

Senomyx, Inc. discovers, develops, and commercializes flavor ingredients and natural high intensity sweeteners primarily for the packaged food, beverage, and ingredient supply industries in the United States. The company develops and/or commercializes sweet, savory and salt flavor ingredients, bitter blockers and cooling agents. It sells various flavor ingredients directly to flavor companies. The company has collaboration agreements with Ajinomoto Co., Inc.; Firmenich SA; and PepsiCo, Inc. Senomyx, Inc. was founded in 1998 and is headquartered in San Diego, California.

About ICON

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.